Kairos Pharma Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets

Kairos Pharma Ltd. (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor targeting non-small cell lung cancer. The company said the proposed acquisition would expand its oncology pipeline with late-preclinical and Phase 1-ready candidates designed to address EGFR mutations and MET-driven resistance mechanisms in NSCLC, a multi-billion dollar market. Kairos indicated that dual inhibition of EGFR and MET pathways could overcome compensatory signaling and extend progression-free survival, positioning the assets for potential monotherapy and combination development pending completion of the transaction.

The acquisition represents a strategic expansion of Kairos Pharma's oncology portfolio, which already includes ENV-105, an antibody targeting CD105 that is currently in Phase 2 clinical trials for castrate-resistant prostate cancer and Phase 1 trials for non-small cell lung cancer. The company's approach utilizes structural biology to overcome drug resistance and immune suppression in cancer, with the new assets potentially addressing significant unmet medical needs in NSCLC treatment. The transaction aligns with Kairos's focus on developing therapies that can reverse drug resistance and restore the effectiveness of standard cancer treatments across multiple cancer types.

Non-small cell lung cancer represents one of the most prevalent and challenging oncology markets, with EGFR mutations and MET-driven resistance mechanisms being key therapeutic targets. The acquisition of CL-273 and CL-741 positions Kairos to potentially address both primary drivers and resistance pathways in NSCLC treatment. The company's latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The full press release for this announcement can be viewed at https://ibn.fm/MPrrW, providing additional details about the transaction and its implications for Kairos Pharma's development pipeline.

The significance of this acquisition extends beyond pipeline expansion to potentially addressing fundamental challenges in NSCLC treatment. By targeting both EGFR and MET pathways, Kairos aims to develop therapies that could overcome the compensatory signaling that often limits the effectiveness of single-pathway inhibitors. This approach could lead to extended progression-free survival for patients and create new treatment paradigms in a market where resistance mechanisms frequently undermine therapeutic benefits. The transaction's completion would mark an important step in Kairos Pharma's strategy to build a comprehensive oncology portfolio targeting multiple resistance mechanisms across different cancer types.